×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ATRA – atara biotherapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ATRA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/21
07:51 am
atra
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) was upgraded by analysts at RODMAN&RENSHAW to a "strong-buy" rating.
Medium
Report
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) was upgraded by analysts at RODMAN&RENSHAW to a "strong-buy" rating.
12/20
08:19 am
atra
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $25.00 price target on the stock.
High
Report
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $25.00 price target on the stock.
12/7
12:40 pm
atra
Updated Results of Phase 3 ALLELE Study Presented at 66th American Society of Hematology Annual Meeting Confirm Efficacy, Safety and Durability of Novel Allogeneic Cell Therapy Tabelecleucel in Relapsed or Refractory Epstein-Barr Virus Positive Post-Trans
Medium
Report
Updated Results of Phase 3 ALLELE Study Presented at 66th American Society of Hematology Annual Meeting Confirm Efficacy, Safety and Durability of Novel Allogeneic Cell Therapy Tabelecleucel in Relapsed or Refractory Epstein-Barr Virus Positive Post-Trans
11/30
07:10 am
atra
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) was upgraded by analysts at TD Cowen to a "strong-buy" rating.
Medium
Report
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) was upgraded by analysts at TD Cowen to a "strong-buy" rating.
11/27
04:01 pm
atra
Atara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx Conference
Low
Report
Atara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx Conference
11/15
07:30 am
atra
Atara Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
Medium
Report
Atara Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
11/13
04:01 pm
atra
Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference
High
Report
Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference
11/13
08:28 am
atra
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) had its price target raised by analysts at Canaccord Genuity Group Inc. from $13.00 to $21.00. They now have a "buy" rating on the stock.
High
Report
Atara Biotherapeutics, Inc. (NASDAQ: ATRA) had its price target raised by analysts at Canaccord Genuity Group Inc. from $13.00 to $21.00. They now have a "buy" rating on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
11/12/2024
04:01 pm
atra
atara biotherapeutics, inc.
BEAT
Report
22.2%
atara biotherapeutics, inc.
8/12/2024
05:00 pm
atra
atara biotherapeutics, inc.
MISS
Report
3.2%
atara biotherapeutics, inc.
5/9/2024
04:01 pm
atra
atara biotherapeutics, inc.
BEAT
Report
-2.9%
atara biotherapeutics, inc.
3/28/2024
08:30 am
atra
atara biotherapeutics, inc.
BEAT
Report
-0.8%
atara biotherapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/23
04:00 pm
atra
Form 8-K Atara Biotherapeutics, For: Dec 20
Medium
Report
Form 8-K Atara Biotherapeutics, For: Dec 20
11/20
06:06 pm
atra
Form 4 Atara Biotherapeutics, For: Nov 18 Filed by: Henrich Jill
High
Report
Form 4 Atara Biotherapeutics, For: Nov 18 Filed by: Henrich Jill
11/20
06:05 pm
atra
Form 4 Atara Biotherapeutics, For: Nov 18 Filed by: Hyllengren Eric J
High
Report
Form 4 Atara Biotherapeutics, For: Nov 18 Filed by: Hyllengren Eric J
11/20
06:04 pm
atra
Form 4 Atara Biotherapeutics, For: Nov 18 Filed by: Nguyen AnhCo
Low
Report
Form 4 Atara Biotherapeutics, For: Nov 18 Filed by: Nguyen AnhCo
11/18
05:59 pm
atra
Form 144 Atara Biotherapeutics, Filed by: Nguyen AnhCo
Medium
Report
Form 144 Atara Biotherapeutics, Filed by: Nguyen AnhCo
11/18
05:57 pm
atra
Form 144 Atara Biotherapeutics, Filed by: Murugan Amar
Medium
Report
Form 144 Atara Biotherapeutics, Filed by: Murugan Amar
11/18
05:56 pm
atra
Form 144 Atara Biotherapeutics, Filed by: Hyllengren Eric J
Low
Report
Form 144 Atara Biotherapeutics, Filed by: Hyllengren Eric J
11/18
05:55 pm
atra
Form 144 Atara Biotherapeutics, Filed by: Henrich Jill
Low
Report
Form 144 Atara Biotherapeutics, Filed by: Henrich Jill
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/19
Atara Biotherapeutics Inc (NASDAQ: ATRA) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating.
25.1%
11/7 Atara Biotherapeutics Announces Third Quarter 2019 Financial Results and Recent Clinical, Operational and Strategic Progress 11.2%
2/5 Atara Biotherapeutics Names Kristin Yarema as Chief Commercial Officer 8.5%
8/9 Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] 6.1%
9/10 Atara Biotherapeutics Inc (NASDAQ: ATRA) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 6.0%
2/27 Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.8%
3/3 Form 4 Atara Biotherapeutics, For: Mar 01 Filed by: Touchon Pascal 5.8%
7/18 Form 424B5 Atara Biotherapeutics, 5.7%
4/22 Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) 5.7%
12/11 Atara Biotherapeutics Inc (NASDAQ: ATRA) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 5.5%
11/7 Atara Biotherapeutics Announces Third Quarter 2019 Financial Results and Recent Clinical, Operational and Strategic Progress 11.2%
2/5 Atara Biotherapeutics Names Kristin Yarema as Chief Commercial Officer 8.5%
8/9 Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] 6.1%
9/10 Atara Biotherapeutics Inc (NASDAQ: ATRA) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 6.0%
2/27 Atara Biotherapeutics, Inc. (ATRA) CEO Pascal Touchon on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.8%
3/3 Form 4 Atara Biotherapeutics, For: Mar 01 Filed by: Touchon Pascal 5.8%
7/18 Form 424B5 Atara Biotherapeutics, 5.7%
4/22 Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) 5.7%
12/11 Atara Biotherapeutics Inc (NASDAQ: ATRA) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 5.5%
TOP News Decliners
5/9
Q1/2019 3/31/2019 EPS -1.440 ZacksConsensus -1.480 ActVsEst 0.040 - Beat
-20.6%
7/16 Atara Biotherapeutics Announces Plan to Initiate Tab-cel® FDA Biologics License Application Submission Next Year -11.9%
2/21 Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) -10.3%
5/12 Atara Biotherapeutics, Inc. 2019 Q1 - Results - Earnings Call Slides [Seeking Alpha] -8.6%
2/19 Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 27, 2020 -8.4%
10/29 Atara Biotherapeutics Inc (NASDAQ: ATRA) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -7.7%
5/7 Atara Biotherapeutics Inc (NASDAQ: ATRA) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. -7.7%
7/16 Atara Biotherapeutics Inc (NASDAQ: ATRA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -7.3%
6/29 Atara Biotherapeutics Presents Initial ATA188 Phase 1 Safety Results for Patients with Progressive Multiple Sclerosis at the 5th Congress of the European Academy of Neurology (EAN) -7.2%
8/1 Atara Biotherapeutics to Announce Second Quarter 2019 Financial Results and Host Conference Call on Thursday, August 8, 2019 -7.1%
7/16 Atara Biotherapeutics Announces Plan to Initiate Tab-cel® FDA Biologics License Application Submission Next Year -11.9%
2/21 Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) -10.3%
5/12 Atara Biotherapeutics, Inc. 2019 Q1 - Results - Earnings Call Slides [Seeking Alpha] -8.6%
2/19 Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 27, 2020 -8.4%
10/29 Atara Biotherapeutics Inc (NASDAQ: ATRA) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -7.7%
5/7 Atara Biotherapeutics Inc (NASDAQ: ATRA) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. -7.7%
7/16 Atara Biotherapeutics Inc (NASDAQ: ATRA) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -7.3%
6/29 Atara Biotherapeutics Presents Initial ATA188 Phase 1 Safety Results for Patients with Progressive Multiple Sclerosis at the 5th Congress of the European Academy of Neurology (EAN) -7.2%
8/1 Atara Biotherapeutics to Announce Second Quarter 2019 Financial Results and Host Conference Call on Thursday, August 8, 2019 -7.1%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: